半嵌合细胞因子诱导的杀伤细胞治疗晚期非小细胞肺癌的疗效

目的 观察半嵌合细胞因子诱导的杀伤细胞（cytokines induced killer cells,CIK）治疗对中晚期非小细胞肺癌患者生存期的影响。方法 回顾性分析2010-2013年在解放军总医院接受治疗的47例中晚期非小细胞肺癌患者。其中观察组24例,对照组23例。观察组为经过半嵌合CIK细胞免疫治疗联合化疗方案的患者,对照组为仅采用化疗方案的患者,比较两治疗组的生存时间和免疫状态。结果 观察组治疗后外周血中总CD3^＋、CD3^＋CD56^＋、CD3^＋CD56^＋CD8^＋细胞百分比显著高于对照组（P〈0.001）;观察组中位无进展生存时间及1年生存率显著高于对照组（7.3个月vs 5.3个月,66.7%vs 41.4%）（P〈0.001）。结论 半嵌合CIK细胞联合化疗治疗非小细胞肺癌可以改善患者机体的免疫状况,有效延长患者生存时间。

Efficacy of semi-allogeneic cytokines induced killer in treatment of non-small cell lung cancer during survival period: A 3-year follow up study

Objective To investigate the survival effect of advanced non-small cell lung cancer treating with semi-allogeneic cytokines induced killer cells （CIK）. Methods Clinical data about 47 patients with advanced non-small cell lung cancer admitted to Chinese PLA General Hospital from 2010 to 2013 were retrospectively analyzed. The patients were divided into two groups, 24 cases of observation group and 23 cases of control group. The observation group received semi-allogeneic CIK cells combined with chemotherapy while the control group was treated with chemotherapy only. Survival time and immune state of the two groups were compared. Results After treatment, the percentage of CD3^＋, CD3^＋CD56^＋, CD3^＋CD56^＋CD8^＋ cell in peripheral blood of the observation group was significantly higher （P 〈 0.05） than that of the control group. The median progression free survival （PFS） and 1-year survival rate of observation group was significantly higher than that of the control group （7.3 months vs 5.3 months, 66.7% vs 41.4%, P 〈 0.001）. Conclusion Semi-allogeneic CIK cells combined with chemotherapy in the treatment of non-small cell lung cancer can improve the patients＇ immune status and prolong patients＇ survival period effectively.